Navigation Links
QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
Date:7/29/2009

ANN ARBOR, Mich., July 29 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena(TM) (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA). The Company has also successfully completed two long term safety extension studies from its first pivotal Phase 3 studies. QuatRx intends to use these results in support of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in early 2010 seeking approval for Ophena(TM), a new SERM (selective estrogen receptor modulator) for the treatment of the symptoms of vulvovaginal atrophy. Ophena(TM) is the only non-estrogen therapy currently in late-stage development for the treatment of vaginal symptoms associated with menopause.

"We are delighted with the progress in our Phase 3 program of Ophena(TM), which provides further evidence of the potential of Ophena(TM) as a first-in-class non-estrogen drug for the treatment of vaginal atrophy, a highly prevalent and symptomatic condition" said Robert L. Zerbe, M.D., Chief Executive Officer of QuatRx. "These new efficacy data confirm results seen in our first phase 3 pivotal study and are an important milestone towards our planned NDA submission."

This second Phase 3 study of Ophena(TM) is a randomized, double-blind, placebo-controlled trial of 919 patients with vulvovaginal atrophy conducted at 116 sites in the United States. Patients were stratified into two cohorts based on their most bothersome moderate to severe vaginal atrophy symptom - either vaginal dryness or dyspareunia (sexual pain). The results announced today focus on the cohort of 314 patients from this study identifying vaginal dryness as their m
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
2. HCA Announces Offering of $750 Million Senior Secured First Lien Notes
3. Mylan Announces Enhancements to Executive Management Team
4. Nfocus Neuromedical Announces European Approval for Novel Guiding Catheter at Society of NeuroInterventional Surgery
5. ONRAD Announces Newly Bundled Services for a Single Package Price
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
7. Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants
8. Zix Corporation Reports Another Record-High Revenue Quarter as Company Announces Second Quarter 2009 Financial Results
9. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
10. NephCure Foundation Announces Research Grant Program Recipients
11. TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at an ... fun!”, she exclaimed. “I’ve always wanted to jump from an ... this would be ok.” , “We put on nylon coveralls, helmets, ... “I don’t remember it being noisy, but the wind was ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her son, ... God does no wrong. , It’s fitting, then, that her ... titled “God Does No Wrong.” It focuses on what happens ... , “My story has a positive message about channeling ... productive, something healing,” Howse said. , “God Does No Wrong” ...
(Date:5/29/2015)... 2015 A group of doctors have discovered ... national effort to teach this “new math” to children in ... been “sickened” by the recent implementation of Common Core Math ... it, Common Core is now a reality in children’s classrooms ... are now seeking ways to improve common core math training ...
(Date:5/29/2015)... The print component of “Skin Health” ... approximately 250,000 and an estimated readership of 750,000. The ... media strategy, and across a network of top news ... of the campaign, click here. , Lucy ... the actress, model and producer details her skin care ...
(Date:5/29/2015)... OncLive proudly announces the 2015 ... recognized by a panel of eminent oncologists for landmark ... Honorees will be introduced and celebrated TONIGHT at the ... 8:30-11:00 p.m. CDT at The Chicago Illuminating Company, 2110 ... recognized for groundbreaking accomplishments, in fields including translational research, ...
Breaking Medicine News(10 mins):Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Turning grief from a child’s passing into virtue 2Health News:Doctors Discover a Cure for the Common Core 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4
... Aaron Margolin, professor of microbiology at the University of ... Disease Laboratory, is available to discuss the science and// ... also known as Norwalk and Norwalk-like viruses, are estimated ... the United States each year. Symptoms include vomiting, diarrhea, ...
... salt-laden foods. The campaign group - Consensus Action on Salt ... excess salt out of food stuff. ,The ... shun salty foods, which will in turn encourage manufacturers to ... avoid buying products which contain either more than 1.25g of ...
... nose, during winter is extremely common. Most people are down ... advice certain protective tips which could// help reduce the number ... and flu viruses are transmitted after contact with an infected ... In the context, they advice, that it is imperative ...
... can travel inside your body, can find if you have ... ,After being swallowed, the robot passes through the ... miniature video camera fitted with the device can capture around ... by Alex Zivanovic of Imperial College, London, and other researchers, ...
... first glance, it is difficult to believe anyone would willingly get ... every year to benefit their health//, and these warm baths have ... sought out the brownish-black mud in Bad Wilsnack in Brandenburg for ... Today, it is also available to those who simply want to ...
... keep the price of a cancer drug affordable for ... asked Swiss pharmaceutical major Novartis// to withdraw its case ... to its anti-cancer medicine. ,"India produces affordable ... in many other developing countries. A patent grant to ...
Cached Medicine News:Health News:Sanitation and Science Prevent Norovirus Spread 2Health News:Germany's Therapeutic Mud Baths Have Healing Qualities 2Health News:Drop Patent Petition, Activists Ask Novartis 2
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... ) has announced the addition of Jain ... and Companies"  to their offering.  ... interference (RNAi) or gene silencing involves the ... inside the cell, this material is processed ...
(Date:5/28/2015)... , May 28, 2015 ... world,s largest provider of health care products and ... practitioners, today reminded its customers that the Henry ... physicians and veterinarians who experience operational, logistical or ... storms in the South Central region of the ...
(Date:5/28/2015)... 28, 2015 AlloSource ®, one ... bone, skin and soft-tissue allografts for use in ... healing, today announced that AlloWrap® DS, its double-sided ... the high-cost reimbursement category. "Reimbursement ... their patients," said Kimberly French , Director ...
Breaking Medicine Technology:Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2
... ChemoCentryx, Inc., today announced that it reported positive Phase ... the American College of Rheumatology (ACR).  CCX354 is an ... chemokine receptor known as CCR1, which is implicated in ... showed that CCX354 was safe and well tolerated by ...
... Sheets: MDBX ) ( www.thedispensingsolution.com ), announced ... MDBX.  The company previously announced that their name was ... company is a leader in the design, manufacture and ... free-standing unit features 60 or more slots that can ...
Cached Medicine Technology:ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4MedBox Announces Ticker Symbol Change 2
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: